Kymera Therapeutics | Company Profile - Revenue, Headcount, Tech Stack, Contacts

Kymera Therapeutics is a clinical-stage biotechnology company focused on developing innovative small molecule medicines through targeted protein degradation (TPD). This approach allows the company to selectively eliminate disease-causing proteins, addressing previously undruggable targets in areas such as immunology. By harnessing the body's natural cellular recycling system, Kymera aims to create therapies for conditions that traditional drugs cannot effectively treat.

The company's platform utilizes oral small molecule degraders that engage the ubiquitin-proteasome system to target harmful proteins. This method offers a promising alternative to injectable biologics, providing patients with convenient oral treatment options. Kymera's robust drug discovery engine supports a pipeline of differentiated programs, including the first oral small molecule degrader in clinical trials for immunological diseases. The company is committed to advancing patient care and tackling significant unmet medical needs through its innovative research and development efforts.